Investment Rating - The report maintains a "Buy" rating for Yili Co., Ltd. (600887.SH) [3][5] Core Views - Yili Co., Ltd. reported a revenue of 90.564 billion yuan for Q1-Q3 2025, a year-on-year increase of 1.71%, while the net profit attributable to shareholders decreased by 4.07% to 10.426 billion yuan. The adjusted net profit increased by 18.73% to 10.103 billion yuan [1] - The company’s liquid milk segment showed stable performance, while other product categories experienced good growth. The liquid milk revenue for Q3 2025 was 18.814 billion yuan, down 8.83% year-on-year, due to rational inventory management during the holiday season. The company maintained stable market share in the ambient milk category, with positive growth in milk beverages and a narrowing decline in ambient yogurt revenue [1][2] - The milk powder and dairy products segment achieved a revenue of 7.683 billion yuan in Q3 2025, up 12.65% year-on-year, driven by effective growth in infant formula and adult nutrition products. The cheese business also maintained rapid growth [1][2] - The cold drink segment reported a revenue of 1.199 billion yuan in Q3 2025, reflecting a year-on-year increase of 17.35%, supported by channel adjustments and continuous product innovation [1] Summary by Sections Financial Performance - For Q1-Q3 2025, the gross margin was 35.48%, while the gross margin for Q3 was 33.92%, reflecting a year-on-year decrease of 1.13 percentage points. The sales expense ratio for Q1-Q3 was 18.28%, showing an improvement in expense efficiency [2] - The net profit margin for Q1-Q3 was 11.51%, with a slight decrease in Q3 to 11.27%. The adjusted net profit margin for Q1-Q3 was 11.16%, with a decrease in Q3 to 10.78% [2] Earnings Forecast and Valuation - The report maintains the profit forecast for 2025-2027, with expected EPS of 1.80, 1.94, and 2.10 yuan, corresponding to P/E ratios of 15, 14, and 13 times respectively. The company is positioned as a leading dairy enterprise with clear medium to long-term advantages [3]

Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company reported a slight decline in revenue and a significant drop in net profit for the first three quarters of 2025, with total revenue of 18.231 billion yuan, down 0.99% year-on-year, and a net profit attributable to shareholders of 87 million yuan, down 25.05% year-on-year [1] - The Shanghai region shows signs of stabilization, while overseas performance is strong, with the company’s subsidiary, Xinlite, improving its operational situation significantly [2][3] - The gross margin has decreased, indicating ongoing pressure on profitability, with a gross margin of 15.04% in Q3 2025, down 3.02 percentage points year-on-year [3] Summary by Sections Financial Performance - For Q3 2025, the company achieved revenue of 5.759 billion yuan, a year-on-year increase of 1.04%, but reported a net loss of 130 million yuan [1] - The revenue breakdown for Q3 2025 shows liquid milk, other dairy products, and livestock products generating 3.540 billion, 1.720 billion, and 189 million yuan respectively, with liquid milk experiencing a year-on-year decline of 8.44% [2] Regional Performance - Revenue from Shanghai, the company's main market, increased by 2.58% year-on-year to 1.711 billion yuan, while revenue from other regions decreased by 7.63% [2] - The overseas market showed a positive trend with an 11.61% increase in revenue [2] Profitability and Cost Structure - The company’s gross margin for Q1-Q3 2025 was 17.65%, while Q3 2025 saw a gross margin of 15.04%, reflecting ongoing cost pressures [3] - Selling expense ratio for Q1-Q3 2025 was 11.51%, increasing to 12.81% in Q3 2025, indicating rising costs in sales efforts [3] Earnings Forecast and Valuation - The profit forecast for 2025-2027 has been revised down significantly, with net profit estimates of 337 million, 390 million, and 463 million yuan respectively, reflecting a reduction of 39.5%, 37.7%, and 34.6% from previous estimates [4] - The current stock price corresponds to a P/E ratio of 35 for 2025, 30 for 2026, and 25 for 2027, indicating a premium valuation despite the challenges [4]

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The company reported a revenue of 7.1 billion yuan for the first three quarters of 2025, a year-on-year increase of 1.9%, with a net profit attributable to shareholders of 1.03 billion yuan, also up 2.7% year-on-year [1]. - In Q3 2025, the skincare segment saw a significant decline in revenue by 20.4%, while the hair care segment experienced remarkable growth of 137.7% [2]. - The gross margin for the first three quarters improved by 3.6 percentage points to 73.7%, while the expense ratio increased by 3.6 percentage points to 55.3% [3]. Summary by Sections Financial Performance - Q3 2025 revenue was 1.74 billion yuan, down 11.6% year-on-year, with net profit at 0.23 billion yuan, down 23.6% year-on-year [1][2]. - The gross margin for Q3 2025 was 74.7%, reflecting a year-on-year increase of 4.0 percentage points [3]. Profitability Forecast - The net profit forecasts for 2025, 2026, and 2027 have been revised downwards by 15%, 14%, and 13% respectively, with projected net profits of 1.53 billion, 1.79 billion, and 2.07 billion yuan [4]. - The earnings per share (EPS) estimates for the same years are 3.86, 4.52, and 5.22 yuan, with corresponding price-to-earnings (P/E) ratios of 20, 17, and 15 [4]. Cash Flow and Inventory Management - Operating cash flow for the first three quarters of 2025 was 1.2 billion yuan, an increase of 196.7% year-on-year [3]. - Inventory as of September 2025 increased by 47.6% from the beginning of the year to 0.98 billion yuan, while accounts receivable decreased by 38.5% to 0.32 billion yuan [3].

要点 事件：公司发布 2025 年三季报，前三季度实现营业收入、归母净利润、扣非归 母净利润分别为 6.92/0.65/0.63 亿元，同比+51.86%/985%/2508%。经营性净 现金流 1.91 亿元，同比转正；EPS（基本）0.13 元。业绩略超市场预期。 点评： 营销改革顺利推进，止咳宝片销量超年初预期。25Q1-Q3 公司营收分别为 2.95/ 1.96/2.01 亿元，同比+79%/31%/41%，持续呈现恢复式增长。今年以来，公司 深化营销组织变革取得积极成效，止咳宝片实施分规格、分渠道销售管理，其中 36 片/盒、48 片/盒、600 片规格均由公司自营团队负责，分别覆盖全国头部连 锁药店、电商平台、第三终端市场，而 24 片/盒规格采用自营+推广服务商的模 式进行推广。25H1 止咳宝片的销量为 3.31 亿片，恢复至 2023 年同期的 61.29%。 25Q1-Q3 止咳宝片的销量实为 4.35 亿片，恢复至 2023 年同期的 64%，超过公 司年初预期，呈现较好的渠道渗透趋势。随着止咳宝片发货数量的显著回升，公 司盈利能力也实现了强劲修复，25Q1-Q3 年公司销售毛利率同比+ ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported better-than-expected performance for Q3 2025, with revenue of 7.48 billion yuan, representing a year-over-year growth of 32.76%, and a net profit of 0.85 billion yuan, up 16.39% year-over-year [1] - The strong performance is attributed to high growth in the front-end business, which generated 5.4 billion yuan in revenue, a year-over-year increase of over 36% [1][2] - The company has improved efficiency and strictly controlled costs, contributing to the positive financial results [1] Summary by Sections Front-end Business - The front-end business, including tool compounds and biochemical reagents, serves as the primary growth engine, maintaining high revenue growth [2] - The molecular building blocks segment has seen a significant increase in customer and order numbers, marking it as a secondary growth engine [2] - As of June 2025, the company has a reserve of over 52,000 tool compounds and biochemical reagents, and approximately 95,000 molecular building blocks, creating a comprehensive compound library [2] Back-end Business - The back-end business, which includes APIs, intermediates, and formulations, has a strong order backlog exceeding 5.9 billion yuan, reflecting a year-over-year growth of 40.1% [3] - The company is enhancing its competitive edge in the XDC segment and has established a strategic layout across Shanghai, Ma'anshan, and Chongqing [3] Financial Forecast and Valuation - The company’s net profit forecasts for 2025 and 2026 have been adjusted to 2.88 billion yuan and 4.00 billion yuan, respectively, with a new forecast for 2027 set at 5.19 billion yuan [3] - The estimated EPS for 2025, 2026, and 2027 are 1.36 yuan, 1.89 yuan, and 2.45 yuan, respectively, with corresponding P/E ratios of 62, 45, and 35 [3]

Investment Rating - The report maintains a "Buy" rating for Yiling Pharmaceutical (002603.SZ) [6] Core Views - The company's Q3 revenue has rebounded, indicating strong growth potential for the full year, particularly with expectations for performance during the flu season [2] - The company has significantly improved its profitability metrics, with gross margin increasing by 7.14 percentage points to 60.53% and net profit margin rising by 8.33 percentage points to 17.05% [2] - The company is a leader in innovative traditional Chinese medicine, benefiting from policy incentives for innovation [4] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while net profit attributable to shareholders increased by 80.33% to 1 billion yuan [1] - Q3 revenue showed a significant improvement, with a quarter-on-quarter increase attributed to the recovery of core product shipments following marketing reforms [2] Research and Development - The company has increased R&D investment, with R&D expenses reaching 544 million yuan, accounting for 9.27% of revenue, a year-on-year increase of 0.29 percentage points [3] - Several innovative drugs have been approved or are in various stages of clinical trials, indicating a robust pipeline for future growth [3] Profit Forecast and Valuation - The profit forecasts for 2025-2027 have been adjusted upwards, with net profit estimates of 1.304 billion yuan for 2025, 1.551 billion yuan for 2026, and 1.779 billion yuan for 2027 [4] - The current price corresponds to a price-to-earnings ratio of 22 for 2025, 19 for 2026, and 16 for 2027, reflecting a favorable valuation [4]

Investment Rating - The report maintains a rating of "Accumulate" for the company [3][5]. Core Views - The company experienced a decline in revenue and net profit in the first three quarters of 2025, with revenue down 11.5% year-on-year to 1.3 billion yuan and net profit down 36.7% to 330 million yuan [1][3]. - The report highlights increased sales expenses and a decrease in gross margin, with the gross margin for the first three quarters down 0.5 percentage points to 81.1% [2][3]. - Due to uncertainties in terminal demand and increasing industry competition, the profit forecasts for 2025-2027 have been revised downwards, with net profit estimates for 2025, 2026, and 2027 adjusted to 460 million yuan, 509 million yuan, and 556 million yuan respectively [3]. Financial Performance Summary - Revenue for the first three quarters of 2025 was 1.3 billion yuan, a decrease of 11.5% year-on-year, with a single-quarter revenue of 430 million yuan in Q3, down 17.6% year-on-year [1]. - The gross margin for the first three quarters was 81.1%, with quarterly margins of 83.0%, 80.6%, and 80.4% for Q1, Q2, and Q3 respectively [2]. - The operating cash flow for the first three quarters was 240 million yuan, a decrease of 48.5% year-on-year [2]. Profitability and Valuation Metrics - The report provides updated earnings per share (EPS) estimates of 0.89 yuan, 0.98 yuan, and 1.07 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings (P/E) ratios of 28, 25, and 23 [3][4]. - The company’s return on equity (ROE) is projected to decline to 8.04% in 2025, with a gradual increase to 9.0% by 2027 [4][12].

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company [1][6]. Core Views - The company reported a significant increase in profit, with a net profit of 167.8 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 60.5% [4]. - The new business value (NBV) showed a robust year-on-year increase of 41.8%, indicating strong growth potential [5]. - The company is focusing on value creation and transformation, with ongoing marketing system reforms and a shift towards floating income-type products [6]. Financial Performance - For the first three quarters of 2025, the company achieved an operating income of 537.9 billion yuan, up 25.9% year-on-year [4]. - The return on equity (ROE) reached 29.3%, an increase of 9.3% compared to the previous year [4]. - The annualized total investment return rate improved by 1.0 percentage point to 6.4% [5]. Business Development - The company’s premium income for the first three quarters was 669.65 billion yuan, reflecting a 10.1% increase year-on-year [5]. - The new single premium income was 218.03 billion yuan, with a year-on-year growth of 10.4% [5]. - The company’s sales force remained robust, with a total of 657,000 sales personnel, maintaining its leading position in the industry [4]. Profit Forecast and Valuation - The profit forecast for the company has been revised upwards, with expected net profits of 173.8 billion yuan, 189.4 billion yuan, and 206.7 billion yuan for 2025, 2026, and 2027 respectively [6][8]. - The current price-to-earnings (P/E) ratio for A-shares is 7.22, while for H-shares it is 3.75, indicating attractive valuation levels [8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is positioned to benefit from dual drivers: the upgrade cycle of major North American clients and the new AI hardware cycle [8] - The company’s growth prospects are supported by traditional business upgrades and new market opportunities in AI hardware [8] Summary by Sections Company Overview - The company operates across five major segments: acoustics, electromagnetic actuation, optics, sensors, and automotive [5] - Recent product showcases include high-energy density speakers and innovative coaxial speaker products [5][6] Acoustics and Electromagnetic Actuation - The company presented a self-developed micro motor solution, enhancing performance metrics significantly [6] - The new vibration motor for the vivo X300 Pro shows improvements in steady-state and transient vibration [6] Optical and Thermal Management - The company achieved breakthroughs in WLG technology, improving yield and capacity [6] - Thermal management solutions are aligned with the demands of high-end devices [6] Market Dynamics - The upgrade cycle for North American clients, particularly the iPhone 17 series, is expected to boost core component orders [7] - The company is positioned as a key supplier for various components, benefiting from increased demand [7] AI Hardware Opportunities - The company is strategically entering the AI hardware market, aligning its technology with the needs of AI edge devices [8] - Collaborations with major brands for AI-related products are underway, setting the stage for future growth [8] Financial Projections - The report forecasts net profits for 2025 at 2.406 billion RMB, with a growth trajectory supported by improving optical business profitability and diversified market opportunities [8][10]

2025 年 10 月 31 日 公司研究 前三季度油气产量显著增长，盈利能力保持韧性 ——中国海油（600938.SH）2025 年三季报点评 买入（维持） 当前价：27.01 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：蔡嘉豪 执业证书编号：S0930523070003 021-52523800 caijiahao@ebscn.com 分析师：王礼沫 执业证书编号：S0930524040002 010-56513142 wanglimo@ebscn.com 25H1 油气产量再创新高，油价波动期盈利 韧性凸显——中国海油（600938.SH）2025 年半年报点评（2025-08-28） 要点 事件： 公司发布 2025 年三季报。2025 年前三季度，公司实现营业总收入 3125 亿元， 同比-4.1%，实现归母净利润 1020 亿元，同比-12.6%。2025Q3 单季，公司实现营 业总收入 1049 亿元，同比+5.7%，环比+4.1%，实现归母净利润 324 亿元，同比 -12.2%，环比-1.6%。 点 ...